Back to category hubs
CATEGORY HUB
Investigational or emerging peptide/peptide-adjacent therapy
This hub separates regulatory meaning from marketing shorthand. Registered, listed, submitted, compounded, cosmetic-listed, or research-use-only does not automatically mean FDA-approved.
Registered is not approved
PeptiLens treats regulatory terms as source-specific facts, not broad claims of safety, legality, or efficacy.
DMF submitted is not approved
PeptiLens treats regulatory terms as source-specific facts, not broad claims of safety, legality, or efficacy.
Cosmetic listed is not clinically proven
PeptiLens treats regulatory terms as source-specific facts, not broad claims of safety, legality, or efficacy.
Matching entries
| Peptide | Evidence | Regulatory | Safety | Reviewed |
|---|---|---|---|---|
| Aviptadil Synthetic vasoactive intestinal peptide | C | Investigational | 3/5 | 6/23/2026 |
| Cagrilintide Long-acting amylin analog peptide | C | Investigational | 3/5 | 6/23/2026 |
| Cilengitide Cyclic RGD peptide integrin inhibitor | C | Investigational | 3/5 | 6/23/2026 |
| Elamipretide Mitochondria-targeted tetrapeptide | C | Investigational | 3/5 | 6/23/2026 |
| Enlicitide decanoate Macrocyclic peptide PCSK9 inhibitor | C | Investigational | 3/5 | 6/23/2026 |
| Mazdutide Dual GLP-1/glucagon receptor agonist peptide | C | Investigational | 3/5 | 6/23/2026 |
| Pemvidutide Dual GLP-1/glucagon receptor agonist peptide | C | Investigational | 3/5 | 6/23/2026 |
| Retatrutide Triple GIP/GLP-1/glucagon receptor agonist peptide | C | Investigational | 3/5 | 6/23/2026 |
| Survodutide Dual GLP-1/glucagon receptor agonist peptide | C | Investigational | 3/5 | 6/23/2026 |
| Ularitide Natriuretic peptide analog | C | Investigational | 3/5 | 6/23/2026 |